Avapritinib's Effect Durable in Indolent Systemic Mastocytosis
(MedPage Today) -- Long-term data from the PIONEER trial, presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, support the durability of response with the KIT inhibitor avapritinib (Ayvakit) for indolent...
Source
MedPage Today
Opens original article in a new tab
